Spots Global Cancer Trial Database for ependymoma
Every month we try and update this database with for ependymoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer | NCT05106296 | Ependymoma Medulloblastoma Glioblastoma Primary Brain T... | Ibrutinib Indoximod Cyclophosphamid... Etoposide | 12 Years - 25 Years | Augusta University | |
| Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors | NCT03194906 | Glioma of Brain Craniopharyngio... Ependymoma Germ Cell Tumor | Memantine Placebo Cognitive Asses... | 6 Years - 21 Years | St. Jude Children's Research Hospital | |
| A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma | NCT04978727 | Medulloblastoma Glioblastoma Mu... Anaplastic Astr... High-grade Astr... Anaplastic Olig... Anaplastic Epen... Ependymoma Diffuse Intrins... | SurVaxM for pat... SurVaxM for pat... SurVaxM for pat... | 1 Year - 21 Years | Pediatric Brain Tumor Consortium | |
| Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2) | NCT04374305 | Neurofibromatos... Vestibular Schw... Non-vestibular ... Meningioma Ependymoma | Brigatinib Neratinib | 12 Years - | Massachusetts General Hospital | |
| Carboplatin and Bevacizumab for Recurrent Ependymoma | NCT01295944 | Ependymoma Anaplastic Epen... | Carboplatin Bevacizumab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Study of BXQ-350 in Children and Young Adults With Relapsed Solid Tumors | NCT03967093 | Neoplasms | BXQ-350 | 1 Year - 30 Years | Bexion Pharmaceuticals, Inc. | |
| MRE Evaluation for Spinal Cord Tumor Surgery: Stiffness and Adhesion Assessment | NCT05957679 | Spinal Cord Tum... | Magnetic Resona... Assessment and ... | 18 Years - 80 Years | Shengjing Hospital | |
| Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor | NCT01171469 | Brain Tumor Glioblastoma Medulloblastoma Ependymoma Anaplastic Astr... | Dendritic Cells Imiquimod | - | Masonic Cancer Center, University of Minnesota | |
| HUMC 1612: Optune NovoTTF-200A System | NCT03128047 | High Grade Glio... Ependymoma | Optune NovoTTF-... | 5 Years - 21 Years | Hackensack Meridian Health | |
| Fatigue, Sleep and Cytokines in Primary Brain Tumor (PBT) Patients | NCT00876499 | Brain Cancer | Questionnaire | 18 Years - | M.D. Anderson Cancer Center | |
| Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma | NCT03478462 | Pediatric Solid... Pediatric Lymph... Pediatric Brain... DIPG Neuroblastoma Ewing Sarcoma Rhabdomyosarcom... Osteosarcoma | CLR 131 | 2 Years - 25 Years | Cellectar Biosciences, Inc. | |
| Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG | NCT03033992 | Malignant Gliom... Ependymoma Diffuse Intrins... | Optune System (... Concurrent Optu... | 3 Years - 21 Years | Pediatric Brain Tumor Consortium | |
| Rare CNS Tumors Outcomes &Risk | NCT03251989 | High Grade Meni... Ependymoma Medulloblastoma PNET Primary CNS Sar... | 18 Years - | National Institutes of Health Clinical Center (CC) | ||
| Study of SBRT Efficacy on Intra and Extra -Cranial Tumors or Metastasis in Pediatrics Population (SBRT Pediatrics) | NCT02013297 | Brain Metastasi... Spinal Tumors Lung Tumors Ependymoma | SBRT treatment | 18 Months - 20 Years | Centre Leon Berard | |
| Multicenter Register for Children and Young Adults With Intracranial Localized Medulloblastoma, CNS-PNET or Ependymoma | NCT02238899 | Medulloblastoma... Cerebral Primit... Ependymoma | - 21 Years | Universitätsklinikum Hamburg-Eppendorf | ||
| Fluorescence Detection of Adult Primary Central Nervous System Tumors With Tozuleristide and the Canvas System | NCT04743310 | Central Nervous... | tozuleristide Canvas imaging ... Surgical resect... | 18 Years - | Cedars-Sinai Medical Center | |
| Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors | NCT03220646 | Brain Tumor | abemaciclib abemaciclib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma | NCT04238819 | Relapsed Solid ... Refractory Soli... | Abemaciclib Irinotecan Temozolomide Dinutuximab GM-CSF | - 21 Years | Eli Lilly and Company | |
| Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma | NCT01032070 | Recurrent or Re... | erlotinib etoposide | 1 Year - 21 Years | Astellas Pharma Inc | |
| HER2-specific Chimeric Antigen Receptor (CAR) T Cells for Children With Ependymoma | NCT04903080 | Ependymoma | HER2 Specific C... | 1 Year - 22 Years | Pediatric Brain Tumor Consortium | |
| Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) | NCT03220035 | Advanced Malign... Ann Arbor Stage... Ann Arbor Stage... Ependymoma Ewing Sarcoma Hepatoblastoma Langerhans Cell... Malignant Germ ... Malignant Gliom... Osteosarcoma Peripheral Prim... Recurrent Child... Recurrent Child... Recurrent Malig... Recurrent Neuro... Refractory Mali... Refractory Neur... Refractory Non-... Refractory Prim... Rhabdoid Tumor Rhabdomyosarcom... Soft Tissue Sar... Wilms Tumor | Laboratory Biom... Vemurafenib | 12 Months - 21 Years | National Cancer Institute (NCI) | |
| A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors | NCT00994071 | Medulloblastoma Pontine Glioma Ependymoma Astrocytoma PNET | Temozolomide ABT-888 | - 21 Years | National Institutes of Health Clinical Center (CC) | |
| Carboplatin as a Radiosensitizer in Treating Childhood Ependymoma | NCT01088035 | Ependymoma | Carboplatin | 12 Months - 21 Years | Ann & Robert H Lurie Children's Hospital of Chicago | |
| MRE Evaluation for Spinal Cord Tumor Surgery: Stiffness and Adhesion Assessment | NCT05957679 | Spinal Cord Tum... | Magnetic Resona... Assessment and ... | 18 Years - 80 Years | Shengjing Hospital | |
| Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification | NCT05259605 | Glioma Glioneuronal Tu... Choroid Plexus ... Pineal Tumors Germ Cell Tumor Tumor of the Se... Diffuse Midline... Ependymoma Embryonal Tumor Pineal Tumor Hemangiopericyt... Hemangioblastom... Melanocytic Tum... | Observational | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Molecular-Guided Therapy for Childhood Cancer | NCT02162732 | Neuroblastoma Medulloblastoma Glioma Ependymoma Choroid Plexus ... Craniopharyngio... Dysembryoplasti... Meningioma Primitive Neuro... Germ Cell Tumor... Rhabdomyosarcom... Non-rhabdomyosa... Ewings Sarcoma Osteosarcoma Wilms Tumor Renal Cell Carc... Malignant Rhabd... Clear Cell Sarc... Liver Tumors | Guided Therapy | 13 Months - 21 Years | Milton S. Hershey Medical Center | |
| Integrated Analysis of Therapy Response and Resistence in Embryonal Tumors and Gliomas | NCT06323408 | Glioma, Maligna... Embryonal Tumor Medulloblastoma Ependymoma | Tissue, blood, ... | 15 Years - 39 Years | University Hospital Regensburg | |
| Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer | NCT05106296 | Ependymoma Medulloblastoma Glioblastoma Primary Brain T... | Ibrutinib Indoximod Cyclophosphamid... Etoposide | 12 Years - 25 Years | Augusta University | |
| Activated Autologous T Cells Against Glioma Cancer Stem Cell Antigens for Patients With Recurrent Glioblastoma | NCT05341947 | Recurrent Gliob... | Activated T cel... | 18 Years - | Cedars-Sinai Medical Center | |
| Antineoplaston Therapy in Treating Patients With Ependymoma | NCT00003479 | Ependymoma | Antineoplaston ... | 6 Months - 99 Years | Burzynski Research Institute | |
| A Trial of Surgery and Fractionated Re-Irradiation for Recurrent Ependymoma | NCT02125786 | Ependymoma | Irradiation Surgery ^1^8F-Fluorodeo... ^1^1C-methionin... Photon therapy Proton therapy | 1 Year - 21 Years | St. Jude Children's Research Hospital | |
| Study of the Effect of GM-CSF on Macrophages in Ependymoma | NCT04408092 | Ependymoma, Rec... Ependymoma | Granulocyte Mac... | 12 Months - 21 Years | University of Colorado, Denver | |
| Natural History Study of Patients With Neurofibromatosis Type 2 | NCT00598351 | Neurofibromatos... | 8 Years - 75 Years | National Institutes of Health Clinical Center (CC) | ||
| Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms | NCT04541082 | Central Nervous... Glioblastoma Gliosarcoma, Ad... Anaplastic Olig... Anaplastic Astr... Pilocytic Astro... Oligodendroglio... Gliomatosis Cer... Pleomorphic Xan... Anaplastic Pleo... Diffuse Midline... Ependymoma Ependymoma, Ana... Medulloblastoma Teratoid Rhabdo... Neuroectodermal... Neuroectodermal... Anaplastic Meni... Atypical Mening... Choroid Plexus ... Pineal Tumor Diffuse Astrocy... Glial Tumor | ONC206 | 18 Years - | Chimerix | |
| Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors | NCT00003926 | Brain and Centr... Childhood Germ ... Chordoma Kidney Cancer Liver Cancer Neuroblastoma Ovarian Cancer Retinoblastoma Sarcoma | amifostine trih... busulfan filgrastim melphalan thiotepa peripheral bloo... | 1 Year - 45 Years | Masonic Cancer Center, University of Minnesota | |
| Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG | NCT03033992 | Malignant Gliom... Ependymoma Diffuse Intrins... | Optune System (... Concurrent Optu... | 3 Years - 21 Years | Pediatric Brain Tumor Consortium | |
| Exploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors | NCT01445288 | Diffuse Intrins... PNET Ependymoma Germinoma Medulloblastoma | 1 Month - 21 Years | National Institutes of Health Clinical Center (CC) | ||
| Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors | NCT00003926 | Brain and Centr... Childhood Germ ... Chordoma Kidney Cancer Liver Cancer Neuroblastoma Ovarian Cancer Retinoblastoma Sarcoma | amifostine trih... busulfan filgrastim melphalan thiotepa peripheral bloo... | 1 Year - 45 Years | Masonic Cancer Center, University of Minnesota | |
| Genetic and Molecular Risk Profiles of Pediatric Malignant Brain Tumors in China | NCT05672043 | Medulloblastoma Central Nervous... Ependymoma Germ Cell Tumor Glioma Brain Tumor, Pe... | 0 Years - 18 Years | Beijing Tiantan Hospital | ||
| Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma | NCT04661384 | Ependymoma Glioblastoma Medulloblastoma Recurrent Metas... | IL13Ralpha2-spe... | 18 Years - | City of Hope Medical Center | |
| Prospective Evaluation of AI R&D Tool in Adult Glioma and Other Primary Brain Tumours (PEAR-GLIO) | NCT06038760 | Brain Tumor Glioma, Maligna... Ependymoma Oligodendroglio... Glioblastoma | Resection | 18 Years - | Ourotech, Inc. | |
| Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) | NCT03220035 | Advanced Malign... Ann Arbor Stage... Ann Arbor Stage... Ependymoma Ewing Sarcoma Hepatoblastoma Langerhans Cell... Malignant Germ ... Malignant Gliom... Osteosarcoma Peripheral Prim... Recurrent Child... Recurrent Child... Recurrent Malig... Recurrent Neuro... Refractory Mali... Refractory Neur... Refractory Non-... Refractory Prim... Rhabdoid Tumor Rhabdomyosarcom... Soft Tissue Sar... Wilms Tumor | Laboratory Biom... Vemurafenib | 12 Months - 21 Years | National Cancer Institute (NCI) | |
| A Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain | NCT01403311 | Glioma | 5-Aminolevuline... | 18 Years - | Legacy Health System | |
| Proton Therapy Research Infrastructure- ProTRAIT- Neuro-oncology | NCT04648462 | Astrocytoma Ependymoma Ganglioglioma Oligodendroglio... Optic Nerve Gli... Meningioma Nerve Sheath Ne... Adenoma Craniopharyngio... Hemangiopericyt... Germinoma Neurilemmoma | ProTRAIT | 18 Years - | Maastricht Radiation Oncology | |
| Immunotherapy for Recurrent Ependymomas in Children Using Tumor Antigen Peptides With Imiquimod | NCT01795313 | Ependymoma | HLA-A2 restrict... Imiquimod enzyme-linked i... flow cytometry immunohistochem... laboratory biom... | 12 Months - 21 Years | University of Pittsburgh | |
| Antineoplaston Therapy in Treating Patients With Ependymoma | NCT00003479 | Ependymoma | Antineoplaston ... | 6 Months - 99 Years | Burzynski Research Institute | |
| Everolimus for Children With Recurrent or Progressive Ependymoma | NCT02155920 | Recurrent Child... | Everolimus | 2 Years - 21 Years | University of Texas Southwestern Medical Center | |
| A Study of Pemetrexed in Children With Recurrent Cancer | NCT00520936 | Osteosarcoma Medulloblastoma Sarcoma, Ewing'... Neuroblastoma (... Neuroblastoma (... Positive Evalua... Rhabdomyosarcom... Ependymoma Non-brainstem H... | pemetrexed | - 22 Years | Eli Lilly and Company | |
| Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors | NCT02574728 | Cancer | Sirolimus Celecoxib Etoposide Cyclophosphamid... | 12 Months - 30 Years | Emory University | |
| Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor | NCT01171469 | Brain Tumor Glioblastoma Medulloblastoma Ependymoma Anaplastic Astr... | Dendritic Cells Imiquimod | - | Masonic Cancer Center, University of Minnesota | |
| Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors | NCT03095248 | Neurofibromatos... Vestibular Schw... Meningioma Ependymoma Glioma | Selumetinib | 3 Years - 45 Years | Children's Hospital Medical Center, Cincinnati | |
| Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma | NCT01096368 | Anaplastic Epen... Brain Ependymom... Cellular Ependy... Clear Cell Epen... Ependymoma Papillary Epend... | 3-Dimensional C... Carboplatin Cisplatin Clinical Observ... Cyclophosphamid... Etoposide Filgrastim Laboratory Biom... Mesna Vincristine | 12 Months - 21 Years | Children's Oncology Group | |
| Fluorescence Detection of Adult Primary Central Nervous System Tumors With Tozuleristide and the Canvas System | NCT04743310 | Central Nervous... | tozuleristide Canvas imaging ... Surgical resect... | 18 Years - | Cedars-Sinai Medical Center | |
| HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors | NCT02457845 | Supratentorial ... Malignant Gliom... Glioblastoma Anaplastic Astr... PNET Cerebral Primit... Embryonal Tumor | G207 | 3 Years - 18 Years | University of Alabama at Birmingham | |
| Social Determinants of Health in Glioblastoma Population | NCT03900689 | Glioma Astrocytoma Oligodendroglio... Ependymoma Ganglioglioma Pleomorphic Xan... | Part 1 Survey G... Part 2 Focus Gr... | 18 Years - | Wake Forest University Health Sciences | |
| Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205 | NCT01247922 | Ependymoma | Erlotinib | 1 Year - 21 Years | Astellas Pharma Inc | |
| A Trial of Surgery and Fractionated Re-Irradiation for Recurrent Ependymoma | NCT02125786 | Ependymoma | Irradiation Surgery ^1^8F-Fluorodeo... ^1^1C-methionin... Photon therapy Proton therapy | 1 Year - 21 Years | St. Jude Children's Research Hospital | |
| Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors | NCT02859857 | Neoplasms | BXQ-350 | 18 Years - 80 Years | Bexion Pharmaceuticals, Inc. | |
| Methotrexate and Etoposide Infusions Into the Fourth Ventricle in Children With Recurrent Posterior Fossa Brain Tumors | NCT02905110 | Brain Tumor Rec... | Methotrexate Etoposide Ommaya Reservoi... | 1 Year - 80 Years | The University of Texas Health Science Center, Houston | |
| Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard Therapy | NCT00463203 | Brain Neoplasms Glioma | Bevacizumab Irinotecan | 18 Years - | Rigshospitalet, Denmark | |
| HER2-specific Chimeric Antigen Receptor (CAR) T Cells for Children With Ependymoma | NCT04903080 | Ependymoma | HER2 Specific C... | 1 Year - 22 Years | Pediatric Brain Tumor Consortium | |
| Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma | NCT01032070 | Recurrent or Re... | erlotinib etoposide | 1 Year - 21 Years | Astellas Pharma Inc | |
| Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors | NCT01836549 | Anaplastic Astr... Anaplastic Epen... Astrocytoma, Gr... Ependymoma Giant Cell Glio... Glioblastoma Gliosarcoma Oligodendroglio... Brainstem Tumor... | imetelstat sodi... | 12 Months - 21 Years | Pediatric Brain Tumor Consortium | |
| Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma and ATRT | NCT01356290 | Medulloblastoma... Ependymoma Recu... ATRT Recurrent | Bevacizumab Thalidomide Celecoxib Fenofibric acid Etoposide Cyclophosphamid... Etoposide phosp... Cytarabine | - 19 Years | Medical University of Vienna | |
| Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors | NCT02689336 | Glioma Rhabdomyosarcom... Osteosarcoma Medulloblastoma Neuroectodermal... Ependymoma Ewing's Sarcoma Wilms Tumor | Erlotinib Temozolomide | 1 Year - 21 Years | Washington University School of Medicine | |
| Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification | NCT05259605 | Glioma Glioneuronal Tu... Choroid Plexus ... Pineal Tumors Germ Cell Tumor Tumor of the Se... Diffuse Midline... Ependymoma Embryonal Tumor Pineal Tumor Hemangiopericyt... Hemangioblastom... Melanocytic Tum... | Observational | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Rare CNS Tumors Outcomes &Risk | NCT03251989 | High Grade Meni... Ependymoma Medulloblastoma PNET Primary CNS Sar... | 18 Years - | National Institutes of Health Clinical Center (CC) | ||
| Study of the Effect of GM-CSF on Macrophages in Ependymoma | NCT04408092 | Ependymoma, Rec... Ependymoma | Granulocyte Mac... | 12 Months - 21 Years | University of Colorado, Denver | |
| Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors | NCT03194906 | Glioma of Brain Craniopharyngio... Ependymoma Germ Cell Tumor | Memantine Placebo Cognitive Asses... | 6 Years - 21 Years | St. Jude Children's Research Hospital | |
| Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors | NCT01836549 | Anaplastic Astr... Anaplastic Epen... Astrocytoma, Gr... Ependymoma Giant Cell Glio... Glioblastoma Gliosarcoma Oligodendroglio... Brainstem Tumor... | imetelstat sodi... | 12 Months - 21 Years | Pediatric Brain Tumor Consortium | |
| Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors | NCT01682746 | Brain Tumor, Re... | Photofrin (porf... | 6 Months - 18 Years | Medical College of Wisconsin | |
| Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors | NCT02502708 | Glioblastoma Mu... Glioma Gliosarcoma Malignant Brain... Ependymoma Medulloblastoma Diffuse Intrins... Primary CNS Tum... | Indoximod Temozolomide Conformal Radia... Cyclophosphamid... Etoposide | 3 Years - 21 Years | Lumos Pharma | |
| Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors | NCT01682746 | Brain Tumor, Re... | Photofrin (porf... | 6 Months - 18 Years | Medical College of Wisconsin | |
| Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard Therapy | NCT00463203 | Brain Neoplasms Glioma | Bevacizumab Irinotecan | 18 Years - | Rigshospitalet, Denmark | |
| Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors | NCT02689336 | Glioma Rhabdomyosarcom... Osteosarcoma Medulloblastoma Neuroectodermal... Ependymoma Ewing's Sarcoma Wilms Tumor | Erlotinib Temozolomide | 1 Year - 21 Years | Washington University School of Medicine | |
| Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma | NCT03727841 | Anaplastic Epen... Ependymoma Ependymomas | Marizomib | - | National Institutes of Health Clinical Center (CC) | |
| Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors | NCT01682746 | Brain Tumor, Re... | Photofrin (porf... | 6 Months - 18 Years | Medical College of Wisconsin | |
| Multicenter Register for Children and Young Adults With Intracranial Localized Medulloblastoma, CNS-PNET or Ependymoma | NCT02238899 | Medulloblastoma... Cerebral Primit... Ependymoma | - 21 Years | Universitätsklinikum Hamburg-Eppendorf | ||
| Carboplatin and Bevacizumab for Recurrent Ependymoma | NCT01295944 | Ependymoma Anaplastic Epen... | Carboplatin Bevacizumab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma and ATRT | NCT01356290 | Medulloblastoma... Ependymoma Recu... ATRT Recurrent | Bevacizumab Thalidomide Celecoxib Fenofibric acid Etoposide Cyclophosphamid... Etoposide phosp... Cytarabine | - 19 Years | Medical University of Vienna |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
